JP2013517307A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013517307A5 JP2013517307A5 JP2012549249A JP2012549249A JP2013517307A5 JP 2013517307 A5 JP2013517307 A5 JP 2013517307A5 JP 2012549249 A JP2012549249 A JP 2012549249A JP 2012549249 A JP2012549249 A JP 2012549249A JP 2013517307 A5 JP2013517307 A5 JP 2013517307A5
- Authority
- JP
- Japan
- Prior art keywords
- lys
- ser
- arg
- glu
- ala
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29665710P | 2010-01-20 | 2010-01-20 | |
| US61/296,657 | 2010-01-20 | ||
| PCT/DK2011/050018 WO2011088837A1 (en) | 2010-01-20 | 2011-01-20 | Treatment of cardiac conditions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016074097A Division JP6200025B2 (ja) | 2010-01-20 | 2016-04-01 | 心臓病の処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013517307A JP2013517307A (ja) | 2013-05-16 |
| JP2013517307A5 true JP2013517307A5 (enExample) | 2014-03-13 |
Family
ID=43928934
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012549249A Withdrawn JP2013517307A (ja) | 2010-01-20 | 2011-01-20 | 心臓病の処置 |
| JP2016074097A Active JP6200025B2 (ja) | 2010-01-20 | 2016-04-01 | 心臓病の処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016074097A Active JP6200025B2 (ja) | 2010-01-20 | 2016-04-01 | 心臓病の処置 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20130157953A1 (enExample) |
| EP (1) | EP2525809B1 (enExample) |
| JP (2) | JP2013517307A (enExample) |
| KR (1) | KR20120128129A (enExample) |
| CN (1) | CN102892425A (enExample) |
| AU (1) | AU2011206979B2 (enExample) |
| BR (1) | BR112012018104A2 (enExample) |
| CA (1) | CA2786934A1 (enExample) |
| CL (1) | CL2012002037A1 (enExample) |
| EA (1) | EA026384B1 (enExample) |
| IL (1) | IL220876A0 (enExample) |
| MX (1) | MX342409B (enExample) |
| NZ (1) | NZ601167A (enExample) |
| PH (1) | PH12012501494A1 (enExample) |
| WO (1) | WO2011088837A1 (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2502218T3 (es) | 2008-12-15 | 2014-10-03 | Zealand Pharma A/S | Análogos de glucagón |
| US8642540B2 (en) | 2008-12-15 | 2014-02-04 | Zealand Pharma A/S | Glucagon analogues |
| AU2008365557A1 (en) | 2008-12-15 | 2011-07-21 | Zealand Pharma A/S | Glucagon analogues |
| MA32970B1 (fr) | 2008-12-15 | 2012-01-02 | Zealand Pharma As | Analogues du glucagon |
| JP6054742B2 (ja) | 2009-07-13 | 2016-12-27 | ジーランド ファーマ アクティーゼルスカブ | アシル化グルカゴン類似体 |
| CN103003300B (zh) | 2010-04-27 | 2017-06-09 | 西兰制药公司 | Glp‑1受体激动剂和胃泌素的肽缀合物及其用途 |
| AR081975A1 (es) * | 2010-06-23 | 2012-10-31 | Zealand Pharma As | Analogos de glucagon |
| CA2802897A1 (en) * | 2010-06-24 | 2011-12-29 | Zealand Pharma A/S | Glucagon analogues |
| KR20140100947A (ko) | 2011-11-03 | 2014-08-18 | 질랜드 파마 에이/에스 | Ｇｌｐ-1 수용체 효능제 펩타이드 가스트린 접합체들 |
| KR20140114845A (ko) * | 2011-12-23 | 2014-09-29 | 질랜드 파마 에이/에스 | 글루카곤 유사체 |
| CA2872314C (en) | 2012-05-03 | 2021-08-31 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
| NZ704043A (en) | 2012-07-23 | 2017-07-28 | Zealand Pharma As | Glucagon analogues |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| AR092873A1 (es) * | 2012-09-26 | 2015-05-06 | Cadila Healthcare Ltd | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| WO2014081872A1 (en) | 2012-11-20 | 2014-05-30 | Mederis Diabetes, Llc | Improved peptide pharmaceuticals for insulin resistance |
| US20150344540A1 (en) * | 2012-12-19 | 2015-12-03 | Novo Nordisk A/S | Novel glp-1 receptor agonists with cholesterol efflux activity |
| HUE035803T2 (en) | 2012-12-21 | 2018-05-28 | Sanofi Sa | Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists |
| BR112015025464A2 (pt) | 2013-04-18 | 2017-10-10 | Novo Nordisk As | coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico |
| AR098065A1 (es) * | 2013-10-17 | 2016-04-27 | Zealand Pharma As | Análogos de glucagón acilados |
| US9988429B2 (en) * | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| AU2014345570B2 (en) * | 2013-11-06 | 2019-01-24 | Zealand Pharma A/S | Glucagon-GLP-1-GIP triple agonist compounds |
| CA2929459C (en) * | 2013-11-06 | 2022-05-03 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
| WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／升糖素受體促效劑 |
| EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
| WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
| AR098616A1 (es) | 2013-12-18 | 2016-06-01 | Lilly Co Eli | Péptido para el tratamiento de hipoglicemia severa |
| CN103724424B (zh) * | 2013-12-27 | 2015-05-27 | 浙江省农业科学院 | 一种mPEG-SPA-pGLP-2复合物及其制备方法和应用 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| JP2017525656A (ja) | 2014-06-04 | 2017-09-07 | ノヴォ ノルディスク アー／エス | 医療用のｇｌｐ−１／グルカゴン受容体コアゴニスト |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| JP2017536343A (ja) * | 2014-10-10 | 2017-12-07 | ノヴォ ノルディスク アー／エス | 安定したｇｌｐ−１ベースのｇｌｐ−１／グルカゴン受容体コアゴニスト |
| EP3212218B1 (en) | 2014-10-29 | 2021-06-30 | Zealand Pharma A/S | Gip agonist compounds and methods |
| KR102418477B1 (ko) * | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
| KR102291020B1 (ko) * | 2014-12-30 | 2021-08-20 | 한미약품 주식회사 | 안정성이 증가된 글루카곤 유도체 |
| WO2016168388A2 (en) * | 2015-04-14 | 2016-10-20 | Palatin Technologies, Inc. | Therapies for obesity, diabetes and related indications |
| PL3283507T3 (pl) | 2015-04-16 | 2020-05-18 | Zealand Pharma A/S | Acylowany analog glukagonu |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| FI3322437T3 (fi) | 2015-06-30 | 2024-02-20 | Hanmi Pharmaceutical Co Ltd | Glukagonijohdannainen ja sen pitkävaikutteisen konjugaatin käsittävä koostumus |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
| JP6712323B2 (ja) | 2015-12-31 | 2020-06-17 | ハンミ ファーマシューティカル カンパニー リミテッド | グルカゴン、ｇｌｐ−１及びｇｉｐ受容体のすべてに活性を有する三重活性体 |
| GB2566228A (en) | 2016-06-09 | 2019-03-06 | AmideBio LLC | Glucagon analogs and methods of use thereof |
| CN122440793A (zh) | 2016-06-29 | 2026-07-24 | 韩美药品株式会社 | 胰高血糖素衍生物、其缀合物、包含其的组合物、和其治疗用途 |
| KR102502040B1 (ko) | 2016-12-09 | 2023-02-24 | 질랜드 파마 에이/에스 | 아실화 glp-1/glp-2 이중 효능제 |
| CN115304666B (zh) * | 2017-11-24 | 2025-09-19 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的胰高血糖素类似物 |
| CN109836503B (zh) * | 2017-11-24 | 2022-09-16 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的多重活性蛋白 |
| TWI912614B (zh) * | 2017-12-21 | 2026-01-21 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| AU2019205905B2 (en) | 2018-01-03 | 2024-12-12 | Mederis Diabetes, Llc | Improved peptide pharmaceuticals for treatment of NASH and other disorders |
| WO2021083306A1 (zh) * | 2019-10-31 | 2021-05-06 | 东莞市东阳光生物药研发有限公司 | Glp-1/gcg双受体激动剂多肽 |
| EP3842060A1 (en) * | 2019-12-23 | 2021-06-30 | Merck Sharp & Dohme Corp. | Stapled lactam co-agonists of the glucagon and glp-1 receptors |
| KR102886870B1 (ko) * | 2020-05-09 | 2025-11-18 | 톈진 인스티튜트 오브 파마슈티컬 리서치 씨오., 엘티디. | 이중 수용체 아고니즘 작용을 갖는 폴리펩티드 유도체 및 그 용도 |
| CN117202924A (zh) | 2020-12-07 | 2023-12-08 | 斯皮特弗尔制药有限责任公司 | 使用glp-1r和gcgr平衡激动剂降低血糖和/或体重的治疗方案和方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6703359B1 (en) * | 1998-02-13 | 2004-03-09 | Amylin Pharmaceuticals, Inc. | Inotropic and diuretic effects of exendin and GLP-1 |
| WO1999040788A1 (en) * | 1998-02-13 | 1999-08-19 | Amylin Pharmaceuticals, Inc. | Inotropic and diuretic effects of exendin and glp-1 |
| AU757658B2 (en) | 1998-03-09 | 2003-02-27 | Zealand Pharma A/S | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| CA2395165C (en) * | 2000-10-20 | 2012-05-22 | Mario Ehlers | Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide |
| GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
| US7192922B2 (en) * | 2002-11-19 | 2007-03-20 | Allegheny-Singer Research Institute | Method of treating left ventricular dysfunction |
| EP2471810A1 (en) | 2006-02-22 | 2012-07-04 | Merck Sharp & Dohme Corporation | Oxyntomodulin derivatives |
| TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
| NZ578948A (en) * | 2007-02-15 | 2012-03-30 | Univ Indiana Res & Tech Corp | Glucagon/glp-1 receptor co-agonists |
| WO2008152403A1 (en) | 2007-06-15 | 2008-12-18 | Zealand Pharma A/S | Glucagon analogues |
| TWI541023B (zh) | 2008-06-17 | 2016-07-11 | 印第安納大學科技研究公司 | 在生理ｐｈ緩衝液中呈現增強之溶解度及穩定性之升糖激素類似物 |
| CA2728284C (en) * | 2008-06-17 | 2019-09-10 | Richard D. Dimarchi | Glucagon/glp-1 receptor co-agonists |
| WO2010107487A2 (en) * | 2009-03-18 | 2010-09-23 | Wu Nian | Lipid-drug conjugates for drug delivery |
| TWI608013B (zh) * | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
-
2011
- 2011-01-20 WO PCT/DK2011/050018 patent/WO2011088837A1/en not_active Ceased
- 2011-01-20 EA EA201290540A patent/EA026384B1/ru not_active IP Right Cessation
- 2011-01-20 BR BR112012018104A patent/BR112012018104A2/pt not_active Application Discontinuation
- 2011-01-20 JP JP2012549249A patent/JP2013517307A/ja not_active Withdrawn
- 2011-01-20 EP EP11704174.9A patent/EP2525809B1/en active Active
- 2011-01-20 CN CN201180012769XA patent/CN102892425A/zh active Pending
- 2011-01-20 NZ NZ601167A patent/NZ601167A/en not_active IP Right Cessation
- 2011-01-20 AU AU2011206979A patent/AU2011206979B2/en not_active Ceased
- 2011-01-20 US US13/574,197 patent/US20130157953A1/en not_active Abandoned
- 2011-01-20 MX MX2012008440A patent/MX342409B/es active IP Right Grant
- 2011-01-20 PH PH1/2012/501494A patent/PH12012501494A1/en unknown
- 2011-01-20 CA CA2786934A patent/CA2786934A1/en not_active Abandoned
- 2011-01-20 KR KR1020127021148A patent/KR20120128129A/ko not_active Abandoned
-
2012
- 2012-07-11 IL IL220876A patent/IL220876A0/en unknown
- 2012-07-20 CL CL2012002037A patent/CL2012002037A1/es unknown
-
2016
- 2016-04-01 JP JP2016074097A patent/JP6200025B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10253080B2 (en) | Glucagon-like-peptide-2 (GLP-2) analogues | |
| AU2011206979B2 (en) | Treatment of cardiac conditions | |
| JP6023048B2 (ja) | グルカゴン類似体 | |
| CN104662038B (zh) | 胰高血糖素类似物 | |
| JP2015517459A5 (enExample) | ||
| JP2015524419A5 (enExample) | ||
| AU2020201322A1 (en) | Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same | |
| RU2017112738A (ru) | Фармацевтические композиции, содержащие варианты пептидов, и способы их применения | |
| JP2018506507A5 (enExample) | ||
| JP2017533194A5 (enExample) | ||
| JP2013543853A5 (enExample) | ||
| JP2014529629A5 (enExample) | ||
| JP2012532898A (ja) | アシル化グルカゴン類似体 | |
| JP2014504597A (ja) | アシル化グルカゴン類似体とインスリン類似体の組合せ物 | |
| EP2025684A1 (en) | Glucagon analogues | |
| JP2013523618A5 (enExample) | ||
| JP2014501712A5 (enExample) | ||
| WO2011134284A1 (zh) | 胰高血糖素样肽-1类似物及其应用 | |
| CA3073011C (en) | Acylated oxyntomodulin peptide analog | |
| JP2015502918A5 (enExample) | ||
| US9200053B2 (en) | Insulin analogues containing penta-fluoro-Phenylalanine at position B24 | |
| AU2013237740B2 (en) | Insulin analogues containing penta-fluora-phenyalanine at position B24 | |
| JP2014205707A5 (enExample) | ||
| JP2014205708A5 (enExample) | ||
| NZ717174B2 (en) | Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same |